Kintara Therapeutics (KTRA) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kintara Therapeutics has postponed its Special Meeting of Stockholders to October 4, 2024, due to insufficient votes on key proposals related to a charter amendment and a strategic merger with TuHURA Biosciences. The adjournment aims to facilitate decisions on increasing Kintara’s authorized shares and the planned merger, which could bolster its solid tumor cancer therapy development.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.
